Tonix Pharmaceuticals appoints industry veteran Ganesh Kamath as Head of Market AccessProactive Investors • 09/30/25
Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market AccessGlobeNewsWire • 09/30/25
Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026GlobeNewsWire • 09/29/25
Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive DisorderGlobeNewsWire • 09/18/25
Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800)GlobeNewsWire • 09/17/25
Tonix Pharmaceuticals Presents Clinical Data on Tonmya™ for the Treatment of Fibromyalgia at PAINWEEK 2025GlobeNewsWire • 09/08/25
Tonix Pharmaceuticals to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2025GlobeNewsWire • 08/28/25
Tonix Pharmaceuticals Soars, Then Sinks: What's Next After Tonmya's Approval (Upgrade)Seeking Alpha • 08/19/25
Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of FibromyalgiaGlobeNewsWire • 08/15/25
Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational HighlightsGlobeNewsWire • 08/11/25
Tonix Pharmaceuticals Announces the Launch of the “Move Fibro Forward” Campaign to Bring Awareness to Individuals Impacted by FibromyalgiaGlobeNewsWire • 07/21/25
Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025GlobeNewsWire • 07/10/25
Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain MedicineGlobeNewsWire • 07/09/25
Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025GlobeNewsWire • 07/07/25
Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal ModelsGlobeNewsWire • 07/02/25
Tonix Pharmaceuticals Announces Inclusion in the Russell 3000® and Russell 2000® IndexesGlobeNewsWire • 06/30/25
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2025GlobeNewsWire • 06/16/25
Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James “Jim” Hunter, to Board of DirectorsGlobeNewsWire • 06/13/25
Tonix Pharmaceuticals Announces Presentation at the 2025 BIO International ConventionGlobeNewsWire • 06/10/25
Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2025GlobeNewsWire • 06/05/25